Inhaled loxapine for acute agitation in a psychiatric emergency service.

IF 1.5 4区医学 Q3 PSYCHIATRY

Annals of Clinical Psychiatry Pub Date : 2021-08-01 DOI:10.12788/acp.0032

Tyler Ruch, Sharon Nuss, Rajashekar Reddy Yeruva, Yonglin Gao, Gulay Tegin, Christina Terrell, Rif S El-Mallakh

{"title":"Inhaled loxapine for acute agitation in a psychiatric emergency service.","authors":"Tyler Ruch, Sharon Nuss, Rajashekar Reddy Yeruva, Yonglin Gao, Gulay Tegin, Christina Terrell, Rif S El-Mallakh","doi":"10.12788/acp.0032","DOIUrl":null,"url":null,"abstract":"Background: Rapid control of agitation in medical settings is necessary for safety and provision of care. Inhaled loxapine achieves peak plasma levels within 2 minutes of administration and is FDA-approved for managing acute agitation.Methods: We examined the use of inhaled loxapine vs non-parenteral treatment as usual (TAU) in a psychiatric emergency service for consecutive patients with acute agitation or aggression. Data were collected retrospectively. T tests were used for continuous variables and Chi-square tests were used for categorical data.Results: A total of 61 patients received inhaled loxapine and 29 received TAU. Time to outcome for patients receiving inhaled loxapine was 21 ± 21 minutes compared with 121 ± 206 minutes for TAU (t =-2.61; P = .014). At outcome, 89% of patients treated with loxapine experienced symptom resolution, compared with 69% of TAU (Chi-square = 17.4, P < .0001). Ten percent of patients receiving loxapine had no change in symptoms and 1% had worsening symptoms vs 14% in the TAU group who experienced no change in symptoms (z = 0.5, not significant), and 17% who described worsening symptoms (z = 6153.9, P < .0001).Conclusions: The rapid absorption of inhaled loxapine is associated with a 6-fold faster and more robust symptom control.","PeriodicalId":50770,"journal":{"name":"Annals of Clinical Psychiatry","volume":"33 3","pages":"162-167"},"PeriodicalIF":1.5000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12788/acp.0032","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}

引用次数: 2

Abstract

Background: Rapid control of agitation in medical settings is necessary for safety and provision of care. Inhaled loxapine achieves peak plasma levels within 2 minutes of administration and is FDA-approved for managing acute agitation.

Methods: We examined the use of inhaled loxapine vs non-parenteral treatment as usual (TAU) in a psychiatric emergency service for consecutive patients with acute agitation or aggression. Data were collected retrospectively. T tests were used for continuous variables and Chi-square tests were used for categorical data.

Results: A total of 61 patients received inhaled loxapine and 29 received TAU. Time to outcome for patients receiving inhaled loxapine was 21 ± 21 minutes compared with 121 ± 206 minutes for TAU (t =-2.61; P = .014). At outcome, 89% of patients treated with loxapine experienced symptom resolution, compared with 69% of TAU (Chi-square = 17.4, P < .0001). Ten percent of patients receiving loxapine had no change in symptoms and 1% had worsening symptoms vs 14% in the TAU group who experienced no change in symptoms (z = 0.5, not significant), and 17% who described worsening symptoms (z = 6153.9, P < .0001).

Conclusions: The rapid absorption of inhaled loxapine is associated with a 6-fold faster and more robust symptom control.

查看原文本刊更多论文

吸入洛沙平治疗精神科急症。

背景:在医疗环境中快速控制躁动是安全和提供护理的必要条件。吸入洛沙平在给药2分钟内达到峰值血浆水平，fda批准用于治疗急性躁动。方法:我们检查了吸入洛沙平与非肠外常规治疗(TAU)在精神科急诊服务中对连续急性躁动或攻击患者的使用。回顾性收集资料。连续变量采用T检验，分类数据采用卡方检验。结果:吸入洛沙平61例，TAU 29例。吸入洛沙平组患者到结果的时间为21±21分钟，TAU组为121±206分钟(t =-2.61;P = .014)。结果显示，89%接受洛沙平治疗的患者症状缓解，而69%接受TAU治疗的患者症状缓解(χ 2 = 17.4, P < 0.0001)。接受洛沙平治疗的患者中，10%的患者症状没有改变，1%的患者症状恶化，而TAU组中，14%的患者症状没有改变(z = 0.5，不显著)，17%的患者症状恶化(z = 6153.9, P < 0.0001)。结论:吸入洛沙平的快速吸收与6倍的更快和更强大的症状控制相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical Psychiatry PSYCHIATRY-

CiteScore

1.80

自引率

7.70%

发文量

审稿时长

>12 weeks

期刊介绍： The ANNALS publishes up-to-date information regarding the diagnosis and /or treatment of persons with mental disorders. Preferred manuscripts are those that report the results of controlled clinical trials, timely and thorough evidence-based reviews, letters to the editor, and case reports that present new appraisals of pertinent clinical topics.